Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLAM family member 7 (SLAMF7), also known as CS1 or CD319, is a type I transmembrane glycoprotein belonging to the signaling lymphocytic activation molecule (SLAM) family of receptors. It functions as a self-ligand receptor involved in immune cell regulation, acting as an activating or inhibitory receptor depending on the cellular context and adaptor protein interactions. It is overexpressed in multiple myeloma and targeted by elotuzumab.
Enhances NK-cell mediated cytotoxicity against tumor plasma cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLAM family member 7 (SLAMF7).